Novel antifungal agents which inhibit lanosterol 14α-demethylase in Candida albicans CCH442

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue 2, 1997, Pages 261-264

  Zakula, Dorothy ^a   Capobianco, John O ^a   Goldman, Robert C ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; LANOSTEROL;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS NIGER; CANDIDA; CRYPTOCOCCUS; DRUG FORMULATION; ENZYME INHIBITION; NONHUMAN; PERIPHERAL NEUROPATHY;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; MICROBIAL SENSITIVITY TESTS; OXIDOREDUCTASES;

EID: 0031052382     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.2.261     Document Type: Article

References (16)

1. White, M. H. (1993). Antifungal prophylaxis. Current Opinions in Infectious Diseases 6, 737-43.
2. Stevens, D. A. (1994). Current status and future directions of antifungal therapy. Infectious Diseases in Clinical Practice 3, Suppl. 2, S97-102.
3. Como, J. A. & Dismukes, W. E. (1994). Oral azole drugs as systemic antifungal therapy. New England Journal of Medicine 330, 263-72.
4. Warnock, D. W. (1992). Azole drug resistance in Candida species. Journal of Medical Microbiology 37, 225-6.
5. Kelly, S. L., Arnoldi, A. & Kelly, D. E. (1993). Molecular genetic analysis of azole antifungal mode of action. Biochemical Society Transactions 21, 1034-38.
6. Hitchcock, C. A. (1993). Resistance of Candida albicans to azole antifungal agents. Biochemical Society Transactions, 21, 1039-47.
7. Parkinson, T., Falconer, D. J. & Hitchcock, C. A. (1995). Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrobial Agents and Chemotherapy, 39, 1696-99.
8. Prasad, R., De Wergifosse, P., Goffeau, A. & Balzi, E. (1995). Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Current Genetics 27, 320-9.
9. Price, M. F., LaRocco, M. T. & Gentry, L. O. (1994). Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrobial Agents and Chemotherapy 38, 1422-7.
10. Shadomy, S., Espinel-lngroff, A. & Cartwright, R. C. (1985). Laboratory studies with antifungal agents: susceptibility tests and bioassays. In Manual of Clinical Microbiology, 4th edn (Lennette, E. H., Balows, A., Hausler, W. J. & Shadomy, H. J., Eds), pp. 991-9. American Society for Microbiology, Washington, DC.
11. Espinel-lngroff, A., Kish, C. W., Kerkering, T. M., Fromtling, R. A., Bartizal, K., Galgiani, J. N. et al. (1992). Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. Journal of Clinical Microbiology 30, 3138-45.
12. Capobianco, J. O., Doran, C. C., Goldman, R. C. & De, B. (1992). A non-azole inhibitor of lanosterol 14α-methyl demethylase in Candida albicans. Journal of Antimicrobial Chemotherapy 30, 781-90.
13. Ryder, N. S., Seidl, G. & Troke, P. F. (1984). Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans. Antimicrobial Agents and Chemotherapy 25, 483-7.
14. Kato, T. & Kawase, Y. (1976). Selective inhibition of the demethylation at C-14 in ergosterol biosynthesis by the fungicide, Denmert (S-1358). Agricultural and Biological Chemistry 40, 2379-88.
15. Vanden Bossche, H., Warnock, D. W., DuPont, B., Kerridge, D., Sen Gupta, S., Improvisi, L. et al. (1994). Mechanisms and clinical impact of antifungal drug resistance. Journal of Medical and Veterinary Mycology 32, Suppl. 1, 189-202.
16. Rex, J. H., Rinaldi, M. G. & Pfaller, M. A. (1995). Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy 39, 1-8.